跳至主要内容
临床试验/NCT00115206
NCT00115206已完成4 期

A Pilot Study of the Effects of Neutropenia on Patient Reported Outcomes During Chemotherapy With or Without Neulasta® (Pegfilgrastim) in Subjects With Advanced NSCLC

Amgen0 个研究点开始时间: 2002年7月1日最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
Amgen
主要终点
Quality of Life

研究概览

简要总结

The purpose of this study is to estimate the relationship between patient reported outcomes (PROs) and neutropenia (or its complications) in NSCLC subjects receiving chemotherapy with or without Neulasta® (pegfilgrastim).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Non-small cell lung cancer, not previously treated with chemotherapy or radiotherapy - ECOG performance status 0 or 1 - ANC greater than or equal to 2.0 x 10^9/L

排除标准

  • Cancer other than NSCLC within 5 years of enrollment, with the exception of surgically cured basal cell carcinoma or in situ carcinoma of the cervix - Treatment less than or equal to 30 days prior with any experimental agent - Subjects with symptomatic brain metastases - Subject is currently enrolled or has not yet completed at least 30 days since ending other investigational device or drug trial(s) or is receiving other investigational agent(s)

结局指标

主要结局

Quality of Life

次要结局

  • Quality of Life, *Neutropenia, *Hospitalization, *Disease Response

研究者

发起方
Amgen
申办方类型
Industry

相似试验